This editorial refers to 'Endothelial nitric oxide synthase of the bone marrow regulates myocardial hypertrophy, fibrosis, and angiogenesis' by A. Kazakov et al., pp. 397-405, this issue.
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Despite the apparent appropriateness of the hypertrophy process, LVH in response to these pathological processes constitutes an independent risk factor for developing angina pectoris and congestive heart failure. 1 The mechanisms underlying the progressive deterioration in LV function remain incompletely understood but include myocardial blood flow abnormalities, as the coronary vascular tree fails to grow commensurate with the degree of LVH. 2, 3 The resulting impaired myocardial O 2 delivery contributes to cardiac contractile dysfunction, apoptosis, and fibrosis. 2, 3 In contrast to LVH produced by MI or pressure overload, LVH produced by regular dynamic physical exercise is associated with a decreased risk for coronary artery disease and congestive heart failure. Indeed, exercise-induced LVH is associated with an increased myocardial perfusion capacity and normal to increased LV contractile function, 4 which is at least partially mediated by endothelial nitric oxide synthase (eNOS)-derived NO.
5
Experimental and clinical studies suggest that eNOS not only contributes to the myocardial and coronary vascular adaptations to exercise, but also modulates LV and vascular remodelling in pathological LVH ( Figure 1) . Thus, eNOS has been shown to ameliorate many of the perturbations observed in cardiac remodelling after MI, including cardiac dysfunction, pulmonary congestion, and interstitial fibrosis, 6 -8 as well as to mediate the beneficial effects of exercise training on these perturbations after MI. 8 In contrast, the evidence of a beneficial influence of endogenous levels of eNOS on cardiac hypertrophy and dysfunction in pressure overload LVH is presently unclear. While some studies suggest a protective effect, 9,10 other studies demonstrated uncoupling of eNOS-elevated oxidative stress thereby aggravating LVH and dysfunction. 11, 12 An explanation for these discrepant findings is not readily found but might be due to the relatively mild degree of LVH in the former 9,10 compared with the latter 11, 12 studies. Importantly, however, eNOS is not only expressed in residential coronary vascular endothelial cells but also in cardiomyocytes 13 and EPCs. 14 Hence, the aforementioned studies, employing global knockout or transgenic eNOS mouse models, 6 -10 do not allow delineation between the contributions of eNOS in each of the various cell types in the heart. This is important, as angiogenesis in the heart not only depends on NO bioavailability 5 but may also involve EPC recruitment from bone marrow (BM). 15 Kazakov et al. 16 therefore assessed the role of eNOS in EPCs in ameliorating pressure overload-induced LVH and dysfunction produced by transverse aortic constriction (TAC An important consequence of this study is that it forces us to consider EPCs as part of the mechanism of the beneficial effect of eNOS in many earlier studies investigating the effects of systemic eNOS knockout or overexpression on cardiovascular disease 6 -11 or on the effects of exercise training. 8 Furthermore, the study demonstrates the two faces of eNOS in cardiovascular disease. Thus, in agreement with more recent studies of TAC-induced severe LVH, 11,12 the degree of LVH and pulmonary congestion produced by TAC were blunted in global eNOS 2/2 compared with WT mice, 16 suggesting that, overall, eNOS exerted a detrimental influence on the pressure-overloaded heart. Similarly, TAC-induced LVH, capillary rarefaction, fibrosis, and pulmonary congestion were aggravated in WT/eNOS 2/2 -BM compared with WT/WT-BM mice. The beneficial influence of eNOS in BM-derived EPCs 16 implies that the overall detrimental influence of eNOS must originate from non-medullary eNOS. Earlier observations that cardiomyocyte-restricted restoration of eNOS activity blunted LVH and dysfunction by TAC in eNOS 2/2 mice 17 could be interpreted to suggest that eNOS uncoupling may occur preferentially in residential coronary endothelial cells. However, the degree of LVH was only moderate in the latter study, 17 which may have prevented uncoupling of cardiomyocyte eNOS. 11, 12 Thus, future studies are required to further elucidate where eNOS (i.e. in which cell type) is susceptible to uncoupling and in which form of LVH ( Figure 1 ). This way, targeted therapy to prevent eNOS uncoupling at its specific location could then be applied, although one might argue that systemic 'eNOS-coupling therapy' with co-factor tetrahydrobiopterin will likely target eNOS at all its locations.
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In conclusion, the study by Kazakov et al. 16 highlights the importance of investigating the role of eNOS in cardiac and extra-cardiac cell types in LVH in order to fully appreciate the two faces of eNOS in modulating cardiac hypertrophy and dysfunction. Furthermore, this elegant study illustrates how, more than 25 years after the discovery of NO, the story of the many ways in which NO contributes to cardiovascular homeostasis continues to unfold.
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